Trial Profile
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 28 Feb 2024
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Paclitaxel (Primary) ; Cisplatin
- Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer
- Focus Therapeutic Use
- 23 Feb 2024 Planned End Date changed from 1 Jan 2024 to 1 May 2024.
- 21 Jan 2023 Primary endpoint has not been met. (Overall survival (OS), as per Results presented at the 2023 Gastrointestinal Cancers Symposium
- 21 Jan 2023 Results presented at the 2023 Gastrointestinal Cancers Symposium